Cytarabine + Daunorubicin Liposomal Suppliers & Bulk Manufacturers
Available Forms: Liposomal injectable
Available Strengths: 44mg/ 100 ml
Reference Brands: Vyxeos
Category:
Liposomal Drug Delivery
Cytarabine + Daunorubicin liposomal (Vyxeos) delivers targeted chemotherapy by encapsulating drugs in liposomes, increasing tumor cell uptake. It inhibits DNA synthesis and promotes cell death. Benefits include enhanced efficacy, reduced toxicity, and improved survival outcomes for acute myeloid leukemia (AML) patients, supporting personalized cancer therapy.
Cytarabine + Daunorubicin liposomal is available in Liposomal injectable
and strengths such as 44mg/ 100 ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cytarabine + Daunorubicin liposomal is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cytarabine + Daunorubicin liposomal can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cytarabine + Daunorubicin liposomal (Vyxeos) is regulated in the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP and MDR standards. In the US, FDA approval involved extensive clinical validation and safety assessments. In the EU, CE marking certifies conformity with MDR regulations. These formulations undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to high-quality liposomal chemotherapies for AML treatment, supporting effective, targeted cancer therapy worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing